Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis

International Urology and Nephrology

Volumn 42, Issue 2, 2010, Pages 441-452

  Niepolski, Leszek ^b   Grzegorzewska, Alicja E ^a   Młot Michalska, Monika ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NONE

Author keywords

Diabetes mellitus; End stage renal disease; EsRAGE; Hemodialysis; Insulin resistance; Visfatin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BODY HEIGHT; BODY MASS; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; ENZYME BLOOD LEVEL; ENZYME GLYCOSYLATION; FEMALE; HEMODIALYSIS; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; THERAPY EFFECT; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 77956190293     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9525-1     Document Type: Article

References (80)

1. Arner P (2006) Visfatin-a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91(1):28-30. doi:10.1210/jc.2005-2391
2. Katakami N, Matsuhisa M, Kaneto H et al (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients. Diabetes Care 28:2716-2721. doi:10.2337/diacare.28.11.2716
3. Filippatos TD, Derdemezis CS, Kiortisis DN et al (2007) Increased plasma levels of visfatin/pre-B cell colony enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30(4):323-326
4. Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587-2593. doi: 10.1161/01.ATV.0000190660.32863.cd
5. Takebayashi K, Suetsugu M, Wakabayashi S et al (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetesmellitus.Metabolism 56(4):451-458. doi:10.1016/j.metabol.2006.12.001
6. Beltowski J (2006) Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 12(6):112-119
7. Axelsson J, Witasp A, Carrero JJ et al (2007) Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 49(2):237-244. doi:10.1053/j.ajkd.2006.11.021
8. Nüsken KD, Petrasch M, Raut M et al (2007) Reduced plasma visfatin in end-stage renal disease is associated with reduced body fat mass and elevated serum insulin. Exp Clin Endocrinol Diabetes 115. doi:10.1055/s-2007-972308
9. Koyama H, Shoji T, Fukumoto S et al (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27:147-153. doi: 10.1161/01.ATV.0000251502.88818.4b
10. Kalousova M, Jachymova M, Mestek O et al (2007) Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020-2026. doi: 10.1093/ndt/gfm050
11. Samal B, Sun Y, Stearns G et al (1994) Cloning and characterization of thecDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437
12. Rongvaux A, Shea RJ, Mulks MH et al (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32(11):3225-3234. doi:10.1002/ 1521-4141(200211)32: 11\3225::AID-IMMU3225[3.0. CO;2-L
13. Fukuhara A,MatsudaM,NishizawaMet al (2005)Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430. doi:10.1126/science.1097243
14. Fukuhara A, Matsuda M, Nishizawa M et al (2007) Retraction. Science 318:565. doi:10.1126/science.318.5850.565b
15. Axelsson J, Heimbürger O, Stenvinkel P (2006) Adipose tissue and inflammation in chronic kidney disease. Obesity and the Kidney. Contrib Nephrol. Basel, Karger 151:165-174. doi:10.1159/000095327
16. Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation endproducts expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1110. doi:10.1042/ BJ20021371
17. Stern DM, Yan SD, Yan FS et al (2002) Receptor for advanced glycation end-products (RAGE) and the complications of diabetes. Ageing Res Rev 1:1-15. doi:10.1016/ S0047-6374(01)00366-369
18. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238. doi:10.1161/01.RES. 0000137876.28454.64
19. Raine AEG (1993) Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulindependent) diabetic patients in Europe. Diabetologia 36:1099-1104. doi:10.1007/BF02374505
20. Lohman TG, Roche AF, Martorel R (1988) Anthropometric standardization reference manual. Human Kinetics, Champaign, IL
21. Daugirdas JT (1993) Second generation logarithmic estimates of single pool variable volumeKt/V: an analysis of error. J Am Soc Nephrol 4:1205-1213
22. Kouw PM, Olthof CG, Wee PM et al (1992) Assessment of post-dialysis dry weight: an application of the conductivity measurement method. Kidney Int 41:440-444. doi: 10.1038/ki.1992.61
23. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419. doi: 10.1007/BF00280883
24. Korantzopoulos P, Elisaf M, Milionis HJ (2007) Multifactoral intervention in metabolic syndrome targeting at prevention of chronic kidney disease-ready for prime time? Nephrol Dial Transplant 22:2768-2774. doi: 10.1093/ndt/gfm525
25. Tzamaloukas AH, Murata GH (2005) Prevention of nephropathy in patients with type 2 diabetes mellitus. Int Urol Nephrol 37:655-663. doi:10.1007/s11255- 005-2394-3
26. DeFronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194. doi:10.2337/ diacare.14.3.173
27. Zanetti M, Barazzoni R, Guarnieri G (2008) Inflammation and insulin resistance in uremia. J Ren Nutr 18(1):70-75. doi:10.1053/j.jrn.2007.10.015
28. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214-E223
29. Yokoyama H, Emoto M, Fujiwara S et al (2003) Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 26:2426-2432. doi:10.2337/diacare.26.8.2426
30. Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63. doi:10.2337/ diacare.23.1.57
31. Emoto M, Nishizawa Y, Maekawa K et al (1999) Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22(5):818-822. doi:10.2337/ diacare.22.5.818
32. Lee SW, Park GH, Lee SW et al (2007) Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 22:2554-2562. doi: 10.1093/ndt/gfm204
33. Shinohara K, Shoji T, Tsujimoto Y et al (2004) Arterial stiffness in predialysis patients with uremia. Kidney Int 65(3):936-943. doi:10.1111/j.1523- 1755.2004.00468.x
34. Ozdemir A, Yalinbas B, SelametUet al (2007) The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients. Yonsei Med J 48(2):274-280
35. Takenaka T, Kanno Y, Ohno Y et al (2007) Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism 56(2):153-159. doi:10.1016/j.metabol. 2006.08.010
36. Nishimura M, Murase M, Hashimoto T et al (2006) Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 69(3):553-559. doi:10.1038/sj.ki.5000100
37. Sit D, Kadiroglu AK, Yilmaz ME et al (2005) The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren Fail 27(4):403-407
38. ShinoharaK, Shoji T, EmotoMet al (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13(7):1894-1900. doi:10.1097/01.ASN.0000019900. 87535.43
39. Adamczak M, Szotowska M, Chudek J et al (2007) Plasma adiponectin concentration in patients after successful kidney transplantation-a single-center, observational study. Clin Nephrol 67(6):381-390
40. Rasic-Milutinovic Z, Perunicic G, Pljesa M (2007) Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med 46(13):945-951. doi:10.2169/ internalmedicine.46. 0092
41. Satirapoj B, Yingwatanadej P, Chaichayanon S et al (2007) Effect of angiotensin II receptor blockers on insulin resistance in maintenance haemodialysis patients. Nephrology (Carlton) 12(4):342-347. doi:10.1111/j.1440- 1797.2007.00770.x
42. Canbakan M, Sahin GM (2007) Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail 29(3):289-293. doi:10.1080/0886022060 1166271
43. Martins C, Mazza do Nascimento M, Pecoits-Filho R et al (2007) Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. J Ren Nutr 17(2):132-137. doi: 10.1053/j.jrn.2006.07.004
44. Gürsu EM, Ozdemir A, Yalinbas B et al (2006) The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol 66(4):263-268
45. Furuya R, Odamaki M, Kumagai H et al (2006) Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 21(2):494-498. doi:10.1093/ndt/gfi197
46. Lin SH, Lin YF, Kuo SW et al (2003) Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 42(4):774-780. doi: 10.1016/S0272-6386(03)00844-8
47. Shoji T, Emoto M, Nishizawa Y (2001) HOMA index to assess insulin resistance in renal failure patients. Nephron 89:348-349. doi:10.1159/000046098
48. Fliser D, Pacini G, Engelleiter R et al (1998) Insulin resistance and hiperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53:1343-1347. doi:10.1046/j.1523-1755.1998.00898.x
49. Kobayashi S, Maesato K, Morija H et al (2005) Insulin resistance in patients with chronic kidney disease renal disease. Am J Kidney Dis 45:275-280. doi:10.1053/ j.ajkd.2004.09.034
50. Kobayashi S, Maejima S, Ikeda T et al (2000) Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 15(1):65-70. doi:10.1093/ndt/15.1.65
51. Stefanovic V, Nesic V, Stojimirovic B (2003) Treatment of insulin resistance in uremia. Int J Artif Organs 26:100-104
52. Kobayashi S, Maejima S, Ikeda T et al (2000) Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous peritoneal dialysis. Nephrol Dial Transplant 15:65-70. doi: 10.1093/ndt/15.1.65
53. Davnay A (2003) Renal clearance of glycation adducts: anti-glycation defence in uraemia and dialysis. Biochem Soc Trans 31(6):1386-1389. doi:10.1042/BST0311386
54. Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38:100-106. doi:10.1053/ajkd.2001. 27414
55. Wells-Knecht KJ, Zyzak DV, Litchfield JE et al (1995) Mechanism of autoxidative glycosylation: inentification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34(11):3702-3709. doi:10.1021/bi00011a027
56. Bierhaus A, Schiekofer S, Schwaninger M (2001) Diabetes- associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792-2808. doi: 10.2337/diabetes.50.12.2792
57. Zoccali C, Mallamaci F, Tripepi G (2004) Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 19(5):67-72. doi:10.1093/ndt/gfh1059
58. Stigant CF, Djurdiev O, Levin A (2005) C-reactive protein levels in patients on maintenance hemodialysis: reliability and reflection on the utility of single measurements. Int Urol Nephrol 37:133-140. doi:10.1007/s11255-004- 2359-y
59. Naoto K, Munehide M, Hideaki K et al (2006) Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. Diabetes Care 29:469
60. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1320
61. Hsieh SD, Yoshinaga H, Muti T (2003) Waist-to-height ratio, a simple and practical index for assessing central fat distribution and metabolic risk in Japanese men and women. Int J Obes 27:610-616. doi:10.1038/sj.ijo.0802259
62. Scaffidi P,Misteli T, BianchiME (2002)Release of chromatin protein HMGB 1 by necrotic cells triggers inflammation. Nature 418:191-195. doi:10.1038/nature00858
63. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126. doi:10.1056/NEJM1999 01143400207
64. Axelsson J, Heimburger O, Lindholm B et al (2005) Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15(1):131-136. doi:10.1053/j.jrn.2004.09.034
65. Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758
66. Kenji O, Kiminori Y, Nozomu K et al (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67(5):796-800. doi:10.1111/j.1365-2265.2007.02966.x
67. Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165-3170. doi:10.1210/jc.2006-0361
68. Dogru T, Sonmez A, Tesci I et al (2006) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76(1):24-29. doi:10.1016/j.diabres. 2006.07.031
69. Nüsken KD, Nüsken E, Petrasch M et al (2007) Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 382:154-156. doi: 10.1016/j.cca.2007.04.004
70. Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin/pre-B cell enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299. doi:10.1210/jc.2005-1475
71. Bae SK, Halestrap AP (2006) Hypoxia induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580:4105-4113. doi:10.1016/j.febslet. 2006.06.052
72. Segawa K, Fukuhara A, Hosogai N et al (2006) Visfatin in adipocytes is upregulated by hypoxia through HIF 1 alphadependent mechanism. Biochem Biophys Res Commun 349:875-882. doi:10.1016/j.bbrc.2006.07.083
73. Nakamura T, Tokunaga K, Shimomura I et al (1994) Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246. doi:10.1016/0021-9150(94) 90025-6
74. Hseih SD, Yoshinaga H (1995) Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor. Int J Obes 19:585-589
75. Cox B, Whichelow MJ (1996) Ratio of waist circumference to height is a better predictor of death than body mass index. BMJ 313:1487
76. Ashwell M, Cole TJ, Dixon AK (1996) Ratio of waist circumference to height is strong predictor of intraabdominal fat. BMJ 313:559-560
77. Ashwell M, Lejeune S (1996) Ratio of waist circumference to height may be better indicator of need for weight management. BMJ 312:377
78. Niepolski L, Grzegorzewska AE, Mlot-Michalska M (2007) Ratio of waist circumference to height (WHeR) as a good predictor of insulin resistance (IR) in non-diabetic patients undergoing intermittent hemodialysis (IHD). J Am Soc Nephrol 18:489A (Abstract)
79. Sanmez A, Dogru T, Tasci I et al (2006) Relationship between plasma visfatin levels and the metabolic variables in metabolic syndrome. Endocr Abstr 11:357
80. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al (2006) Serum visfatin increases with progressive b-cell deterioration. Diabetes 55:2871-2875. doi:10.2337/db06- 0259